Literature DB >> 21208927

Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.

Matthew J Memoli1, A Sally Davis, Kathleen Proudfoot, Daniel S Chertow, Rachel J Hrabal, Tyler Bristol, Jeffery K Taubenberger.   

Abstract

BACKGROUND: The 2009 influenza A(H1N1) pandemic called attention to the limited influenza treatment options available, especially in individuals at high risk of severe disease. Neuraminidase inhibitor-resistant seasonal H1N1 viruses have demonstrated the ability to transmit well despite early data indicating that resistance reduces viral fitness. 2009 H1N1 pandemic viruses have sporadically appeared containing resistance to neuraminidase inhibitors and the adamantanes, but the ability of these viruses to replicate, transmit, and cause disease in mammalian hosts has not been fully characterized.
METHODS: Two pretreatment wild-type viruses and 2 posttreatment multidrug-resistant viruses containing the neuraminidase H275Y mutation collected from immunocompromised patients infected with pandemic influenza H1N1 were tested for viral fitness, pathogenicity, and transmissibility in ferrets.
RESULTS: The pretreatment wild-type viruses and posttreatment resistant viruses containing the H275Y mutation all demonstrated significant pathogenicity and equivalent viral fitness and transmissibility.
CONCLUSIONS: The admantane-resistant 2009 pandemic influenza A(H1N1) virus can develop the H275Y change in the neuraminidase gene conferring resistance to both oseltamivir and peramivir without any loss in fitness, transmissibility, or pathogenicity. This suggests that the dissemination of widespread multidrug resistance similar to neuraminidase inhibitor resistance in seasonal H1N1 is a significant threat.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21208927      PMCID: PMC3071106          DOI: 10.1093/infdis/jiq067

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  The isolation of Listeria monocytogenes from ferrets.

Authors:  J A MORRIS; M C NORMAN
Journal:  J Bacteriol       Date:  1950-02       Impact factor: 3.490

2.  Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification.

Authors:  A E Krafft; K L Russell; A W Hawksworth; S McCall; M Irvine; L T Daum; J L Connoly; A H Reid; J C Gaydos; J K Taubenberger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

4.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.

Authors:  Rick A Bright; Marie-jo Medina; Xiyan Xu; Gilda Perez-Oronoz; Teresa R Wallis; Xiaohong M Davis; Laura Povinelli; Nancy J Cox; Alexander I Klimov
Journal:  Lancet       Date:  2005-09-22       Impact factor: 79.321

5.  Universal primer set for the full-length amplification of all influenza A viruses.

Authors:  E Hoffmann; J Stech; Y Guan; R G Webster; D R Perez
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

6.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Authors:  L V Gubareva; L Kaiser; M N Matrosovich; Y Soo-Hoo; F G Hayden
Journal:  J Infect Dis       Date:  2001-01-11       Impact factor: 5.226

7.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Authors:  J A L Ives; J A Carr; D B Mendel; C Y Tai; R Lambkin; L Kelly; J S Oxford; F G Hayden; N A Roberts
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

8.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.

Authors:  J Carr; J Ives; L Kelly; R Lambkin; J Oxford; D Mendel; L Tai; N Roberts
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

10.  Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.

Authors:  M L Herlocher; J Carr; J Ives; S Elias; R Truscon; N Roberts; A S Monto
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

View more
  39 in total

Review 1.  Fitness of neuraminidase inhibitor-resistant influenza A viruses.

Authors:  Tatiana Baranovich; Robert G Webster; Elena A Govorkova
Journal:  Curr Opin Virol       Date:  2011-10-01       Impact factor: 7.090

2.  The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.

Authors:  Lady Tatiana Pinilla; Benjamin P Holder; Yacine Abed; Guy Boivin; Catherine A A Beauchemin
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

3.  Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Authors:  Andrés Pizzorno; Yacine Abed; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.

Authors:  Natalia A Ilyushina; Nicolai V Bovin; Robert G Webster
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Joyce Jones; Juan A De La Cruz; Katrina Sleeman; Daisuke Tamura; Ha T Nguyen; Ho-Sheng Wu; Feng-Yee Chang; Ming-Tsan Liu; Alicia M Fry; Nancy J Cox; Julie M Villanueva; Charles T Davis; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2014-08-14       Impact factor: 5.226

Review 7.  Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.

Authors:  Elena A Govorkova
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

8.  Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Authors:  Yacine Abed; Andrés Pizzorno; Xavier Bouhy; Chantal Rhéaume; Guy Boivin
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 9.  Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents.

Authors:  Nela Malatesti; Ivana Munitic; Igor Jurak
Journal:  Biophys Rev       Date:  2017-03-24

10.  3-Hydroxyquinolin-2(1H)-ones As Inhibitors of Influenza A Endonuclease.

Authors:  Hye Yeon Sagong; Ajit Parhi; Joseph D Bauman; Disha Patel; R S K Vijayan; Kalyan Das; Eddy Arnold; Edmond J LaVoie
Journal:  ACS Med Chem Lett       Date:  2013-05-07       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.